Janssen Pharmaceutical Companies Of Johnson & Johnson Today Announced Its Decision To Stop The Phase 3 Maciteph Study Evaluating Macitentan 75 Mg In Patients With Chronic Thromboembolic Pulmonary Hypertension Due To Futility
Portfolio Pulse from Charles Gross
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has decided to halt the Phase 3 MACiTEPH study evaluating macitentan 75 mg in patients with Chronic Thromboembolic Pulmonary Hypertension due to futility. The decision was made following a recommendation by the study’s independent data monitoring committee after a pre-planned interim analysis. The interim results do not impact any of the company's commercialized pulmonary hypertension medicines.
September 06, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Johnson & Johnson's subsidiary, Janssen Pharmaceutical, has halted a Phase 3 study due to futility. This does not impact any of the company's commercialized pulmonary hypertension medicines.
The halt of the Phase 3 study is a setback for Janssen Pharmaceutical and Johnson & Johnson, but the company has clarified that this does not impact any of their commercialized pulmonary hypertension medicines. Therefore, the short-term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100